Get the app
NSEHealthcare

Wanbury Limited (WANBURY)

NSE · Healthcare · Drug Manufacturers - Specialty & Generic

₹223.65+0.47%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
₹166 cr
Revenue YoY
+1.5%
Net profit
₹3 cr
Profit YoY
-76.0%
Net margin
2.0%

Key statistics

Market cap
₹844 cr
P/E
15.0
Forward P/E
0.0
P/B
6.00
Book value
₹48.32
EPS (TTM)
₹16.10
52-week high
₹358.85
52-week low
₹161.50
50-day MA
₹282.03
200-day MA
₹255.60
Beta
-0.18

Shareholding

Promoters
51.31%
Institutions
2.08%

Recent filings & reports

DocumentDate
Annual report FY2026
WANBURY LIMITED – ANNUAL REPORT 2025-26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Total Revenue: ₹65,026.83 lakhs (FY 2025-26) vs ₹59,951.42 l
2026-08-31
Quarterly results · Q1 FY27
WANBURY LIMITED - Q1 FY27 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from Operations: Rs. 165.6 crore (Q1 FY27) vs Rs. 163.2 crore (Q1 FY26) – gro
2026-08-11
Investor presentation · Q1 FY27
WANBURY LIMITED - INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Total Revenue: ₹650.26 crore (8% YoY growth from ₹599.51 crore in FY25) • FY26 EBITDA: ₹1
2026-07-01
Investor presentation · Q4 FY26
WANBURY LIMITED - DOCUMENT SUMMARY OTHER NOTABLE POINTS • Company organizing plant visit and management meeting for investors/analysts on 05.06.2026
2026-06-02
Quarterly results · Q4 FY26
WANBURY LIMITED - FY2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹650.3 Cr in FY26 vs ₹599.5 Cr in FY25 (+8.5% YoY) • EBITDA:
2026-06-02
Quarterly results · Q3 FY26
WANBURY LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Stock Options Granted: 91,500 employee stock options (ESOPs) under Wanbury ESOP 2016 • Exercis
2026-03-05
Investor presentation
WANBURY LIMITED – INVESTOR SUMMARY Q3 & 9M FY26 (Nine Months Ended 31 December 2025) --- HEADLINE NUMBERS • 9M FY26 Revenue: ₹485.69 crore (up 13.6
2026-02-09
Investor presentation · Q2 FY26
WANBURY LIMITED - FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • H1FY26 Revenue: ₹323.2 crore, up 10.6% YoY (from ₹292.3 crore H1FY25) •
2025-11-24

Readable in the app.

Deals & corporate news

AnnouncementDate
Launches commercial production of key anaesthetic API at facility
Wanbury Limited, a pharmaceutical company, has announced the commercial launch of production for a key anaesthetic active pharmaceutical ingredient (API) at its Tanuku facility in India. Thi
2026-01-28

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Wanbury Limited — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.